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Abstract
We investigated the speciﬁcity of superparamagnetic iron
oxide (SPIO)–enhanced T1-weighted spin-echo (SE) mag-
netic resonance (MR) images for the characterization of liver
hemangiomas. When imaging liver hemangiomas, which are
the most frequent benign liver tumors, a method with very
high speciﬁcity is required, which will obviate other studies,
follow-up, or invasive diagnostic procedures such as percu-
taneous biopsy. Eighty-three lesions were examined by MR
imaging at 1.5 T before and after intravenous injection of
SPIO particles. Lesions were categorized as follows accord-
ing to the ﬁnal diagnosis: 37 hemangiomas, nine focal nod-
ular hyperplasias (FNHs), 19 hepatocellular carcinomas
(HCCs), and 18 metastases. Their signal intensity values
were normalized to muscle and compared. The only lesions
showing a signiﬁcant increase in signal intensity ratio (lesion
to muscle) on postcontrast T1-weighted SE images were
hemangiomas (p  0.001). The signal intensity ratio of
hemangiomas increased on average by 70%. Based on re-
ceiver operating characteristic analysis and using a cutoff
level of 50% signal increase, the speciﬁcity and sensitivity of
SPIO-enhanced MR imaging for the characterization of
hemangiomas would be 100% and 70%, respectively. The
T1 effect of SPIO particles can help differentiate hemangi-
omas from other focal liver lesions such as FNHs, HCCs,
and metastases and may obviate biopsy. When using SPIO
particles for liver imaging, it is useful to add a T1-weighted
sequence to T2-weighted images, thereby providing addi-
tional information for lesion characterization.
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Hemangiomas are the most common benign liver tumor and,
in the vast majority of cases, do not require surgical treat-
ment [1]. It is therefore important that an imaging-based
diagnosis can be made with high speciﬁcity to avoid unnec-
essary complementary examinations or invasive procedures
such as percutaneous biopsy or even surgery.
When using ultrasound (US), typical hemangiomas ap-
pear as sharply delineated, hyperechoic lesions [2, 3]. In
such cases, the diagnosis is easily made. It is more difﬁcult
in atypical hemangiomas or when there is a fatty liver, in
which hemangiomas are frequently seen as iso- or even
hypoechoic lesions [4]. US thus lacks characteristic features,
and differentiating hemangiomas from other lesions, such as
liver metastases, can be unreliable. Computed tomography
(CT) has a good sensitivity for the diagnosis of hemangio-
mas [5, 6]. However, hemangiomas may have atypical fea-
tures, for example, intense homogeneous arterial
enhancement and early fading [7]. Hemangiomas larger than
3 cm in diameter or smaller than 1 cm rarely show typical
enhancement [8]. Moreover, in oncologic patients, charac-
terization of liver nodules is much more critical. Thus,
whereas in the general population the diagnosis of heman-
gioma is made accurately in 76% of cases, this percentage
falls to 48% in patients with cancer [9].
Magnetic resonance imaging (MRI) has been proposed by
many investigators [5] for the characterization of hemangi-
omas. MRI is quite sensitive for the detection of hemangi-
omas. A T2-weighted sequence is mandatory for the
characterization of liver hemangiomas. Moreover, theCorrespondence to: X. Montet; email: xavier.montet@hcuge.ch
Abdominal
Imaging
© Springer-Verlag New York, Inc. 2003
Received: 14 May 2003 / Revision accepted: 16 July 2003 / Published online: 31 October 2003
Abdom Imaging (2004) 29:60–70
DOI: 10.1007/s00261-003-0092-0
heavier the T2 weighting of the sequence, the more reliable
the differential diagnosis [10, 11]. The adjunction of a dy-
namic gadolinium chelate-enhanced T1-weighted sequence
increases the accuracy of the diagnosis of liver hemangiomas
as compared with native T2-weighted images alone [12].
Nevertheless, the diagnostic accuracy of MRI for the char-
acterization of liver hemangiomas has limitations. Shimizu
et al. reported cases in which benign lesions were operated
because of a diagnosis of malignancy [13]. On the one hand,
in most of the patients, the lesions misinterpreted as malig-
nant were hemangiomas and focal nodular hyperplasia
(FNH). On the other hand, to call benign a malignant lesion
can have deleterious consequences [14].
In this retrospective study, we evaluated the usefulness of
superparamagnetic iron oxide (SPIO) particles for the char-
acterization of hemangiomas. Several studies have demon-
strated that SPIO particles improve detection of
hepatocellular carcinoma (HCC) [15, 16] or metastasis by
using their ability to be phagocytosed by Kupffer cells and to
be clustered within them. In this situation, the r2 relaxivity of
SPIO particles is very high, which leads to a decrease of T2*
of liver parenchyma. However, one also can take advantage
of their r1 relaxivity. As with other MRI contrast agents, the
T1 effect of SPIO particles predominates at low concentra-
tion, which is the case in hemangiomas, where SPIO parti-
cles are diluted in the blood pool and are not clustered.
The aim of this study was to evaluate whether SPIO
particles could distinguish hemangiomas from other focal
liver lesions, with a focus on the speciﬁcity of the T1 effect
of SPIO particles, and thus to conﬁrm ﬁndings previously
published in a pilot study [17].
Materials and methods
This study was performed after acceptance by the ethics
committee of our institution. Forty-six patients with 83 focal
liver lesions were studied with SPIO-enhanced MRI. Pa-
tients were referred for MRI examination to our institution
for characterization of focal liver nodules seen on US and/or
CT in patients without previous history of cancer (n  30),
assessment of liver metastases (n  7), or HCC (n  9). All
the consecutive examinations seen in MRI for liver lesion
characterization were retrospectively retrieved by using the
Radiology Information System of our department and the
American College of Radiology coding system.
Standards of references (“gold standards”)
Based on the clinical ﬁles, including reports from the surgi-
cal and the pathologic departments and radiologic examina-
tions other than MRI, the cases were categorized as
hemangiomas, FNHs, metastases, or HCCs.
The following criteria, ordered according to decreasing
weighting, were used for the classiﬁcation of the lesions, as
indicated in Table 1: surgical (or autopsy) and histologic
ﬁndings, percutaneous biopsy and histologic ﬁndings, typi-
cal CT ﬁndings for hemangiomas and FNHs, clinical fol-
low-up for hemangiomas, FNHs, metastases, and HCCs.
The CT studies were independently analyzed by three
radiologists who did not participate in the reading of the
MRI examinations. CT ﬁndings were considered as typical,
if all three radiologists reported them as such, according to
the following criteria.
1. Hemangiomas: strong globular peripheral enhancement,
isodense with the aortic blood, during the hepatic arterial
Table 1. Standards of referencea
Patient Diagnosis Biopsy Typical
CT
ﬁndings
Clinical
follow-up
(years)Surgical Percutaneous
1 Hemangioma 6
2 Hemangioma 3
3 Hemangioma * 5
4 Hemangioma * 4
5 Hemangioma * 5
6 Hemangioma * 6
7 Hemangioma * 3
8 Hemangioma * 2
9 Hemangioma * 5
10 Hemangioma * 2
11 Hemangioma * 2
12 Hemangioma 
FNH
* * 5
13 Hemangioma 3
14 Hemangioma * * 4
15 Hemangioma * 2
16 Hemangioma 4
17 Hemangioma * 4
18 Hemangioma * 3
19 Hemangioma * 4
20 Hemangioma 
metastases
2
21 HNF *
22 HNF *
23 HNF * 2
24 HNF *
25 HNF *
26 HNF *
27 HNF *
28 HNF *
29 Metastases *
30 Metastases *
31 Metastases *
32 Metastases *
33 Metastases *
34 Metastases *
35 Metastases *
36 Metastases
37 HCC *
38 HCC *
39 HCC *
40 HCC *
41 HCC *
42 HCC *
43 HCC *
44 HCC *
45 HCC *
46 HCC *
CT, computed tomography; FNH, focal nodular hyperplasia; HCC, hepa-
rocellular carcinoma
aGold standard used in this study
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phase, followed by centripetal ﬁlling during the portal
venous phase and the delayed phase (the acquisition of
the latter phase was not mandatory) [18, 19]
2. Focal nodular hyperplasias: strong enhancement of a
well-deﬁned (lobulated) lesion in the arterial phase with a
hypodense central scar, followed by a rapid washout
during the portal phase, so that the lesion was iso- or
slightly hyperdense relative to normal liver; isodensity
relative to normal liver and hyperattenuating central scar
[5] during the delayed phase (the acquisition of the latter
phase was not mandatory).
The clinical follow-up as criterion for lesion character-
ization was evaluated in the following way.
1. Hemangiomas: no change in size over at least a 2-year
period of a lesion, which on CT showed peripheral en-
hancement without clear globular enhancement [20, 21]
2. Focal nodular hyperplasias: no change in size over at least
a 2-year period of a lesion, which on CT was hypervas-
cular in the hepatic arterial phase and showed rapid
washout in the portal-venous phase [5] but no central scar
3. Metastases: focal lesion increasing in size in a patient
with known malignancy
4. Hepatocellular carcinomas: focal lesion increasing in size
in a patient with known cirrhosis
MRI examinations
These examinations were done on a 1.5-T Eclipse system
(Marconi Medical Systems, Cleveland, OH, USA). The fol-
lowing imaging sequences were used:
1. Spin echo (SE) T1-weighted (repetition time [TR]  480
ms, echo time [TE]  8 ms, ﬁeld of view  35–40 cm,
matrix  256  256, section thickness  10 mm, one
signal acquired). We used an SE T1-weighted sequence
instead of a ﬁeld echo sequence to minimize the T2*
effect.
2. Fast SE (FSE) T2-weighted (TR  4660 ms, TE  112
ms, echo train length  8, ﬁeld of view  35–40 cm,
matrix  512  512, section thickness  10 mm, one or
two signals acquired). The choice of a TE of 112 ms was
dictated by a compromise between a long TE value for
lesion characterization and an acceptable signal-to-noise
ratio.
The same sequences were obtained before and after in-
jection of SPIO particles (Ferumoxides, Endorem, Guerbet,
Aulnay-sous-Bois, France) at a dose of 15 mol Fe/kg body
weight. For the administration of SPIO particles, the patients
were taken out of the MRI unit. The contrast agent was
perfused slowly over 30 min. The patients were then asked to
return into the magnet for the second part of the examination.
Care were taken to place the patients in the same position by
using the laser device of the MR unit. The postcontrast
sequences were acquired between 1 and 1.5 h postinjection
of SPIO particles.
Image analysis
The MR images were reviewed in conference by two radi-
ologist (F.T., X.M.) who established a diagnosis in consen-
sus. They were blinded to clinical information at the time of
review. The number, localization, and morphologic aspect of
the lesions were noted, especially whether they were hypo-,
iso-, or hyperintense relative to liver parenchyma. In addi-
tion, the signal intensity ratio of the lesion was calculated.
The ratio refers to the intensity of the lesions divided by the
signal intensity of the paraspinal musculature. Data are pre-
sented as mean  standard deviation.
We applied Student’s t tests to all our results, with p 
0.05 considered statistically signiﬁcance.
At the end of the study, using the signal intensity ratio on
the precontrast T2-weighted and postcontrast T1-weighted
sequences of all 83 lesions, we constructed receiver operat-
ing characteristic (ROC) curves. On the curves, we deter-
mined the point nearest to the upper right corner,
corresponding to the best sensitivity and speciﬁcity couple of
the test. We also calculated the area under the curve (AUC)
and compared the curves of the precontrast T2-weighted and
postcontrast T1-weighted sequences. Thus we could evaluate
the use of SPIO-enhanced T1-weighted sequence with the
nonenhanced T2-weighted sequence. The latter is the tradi-
tional method for characterizing hemangiomas with MRI.
Results
The patients were grouped into the following categories,
according to the criteria deﬁned under Standards of Refer-
ence (“Gold Standards”) (Table 1):
Categorization
Hemangiomas
Thirty-seven hemangiomas were found in 20 patients. Pa-
tients’ mean age was 49.5 ( 10.2) years. The male-to-
Table 2. Signal ratios of focal liver lesion on magnetic resonance imaging
sequencesa
Lesion SE T1-weighted FSE T2-weighted
Pre-SPIO Post-SPIO Pre-SPIO Post-SPIO
Hemangioma 1.13 (0.34)b 1.92 (0.66)b 6.46 (4.42)c 3.73 (2.01)c
FNH 1.50 (0.28) 1.62 (0.40) 2.96 (0.45)c 1.88 (0.72)c
Metastases 1.71 (0.79) 1.58 (0.74) 3.14 (1.85) 3.18 (2.40)
HCC 1.99 (0.49) 1.92 (0.35) 2.46 (0.57) 3.49 (1.47)
aResults are given as mean ( standard deviation)
bp  0.001
cp  0.05
FNH, focal nodular hyperplasia; FSE, fast spin echo; HCC, hepatocellular
carcinoma; SE, spin echo; SPIO, superparamagnetic iron oxide
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female ratio was seven to 13. The mean size of the
hemangiomas was 19.8 ( 12.4) mm, with a range between
4 and 64 mm. The diagnosis was conﬁrmed by surgical
biopsies (n  1, giant hemangioma with Kasabach-Merritt
syndrome), typical CT ﬁndings (n  13), or clinical fol-
low-up (n  6; Table 1).
Focal nodular hyperplasias
Nine FNHs were found in eight patients. Patients’ mean age
was 40 years ( 12). The male-to-female ratio was two to
six. The mean size of the FNHs was 33 mm ( 12), with a
range between 12 and 54 mm. The diagnosis was conﬁrmed
by surgical biopsy (n  4), percutaneous biopsy (n  4), or
clinical follow-up (n  1; Table 1).
Metastases
Eighteen metastases were found in eight patients. Patients’
mean age was 55 years ( 15). The male-to-female ratio was
six to two. The mean size of the metastases was 25 mm
( 15), with a range between 11 and 68 mm. The diagnosis
was conﬁrmed by surgical biopsy (n  4), percutaneous
biopsy (n  3), or clinical follow-up (n  1; Table 1).
Hepatocellular carcinomas
Nineteen HCCs were found in 10 patients. Patients’ mean
age was 63 years ( 11). The male-to-female ratio was eight
to two. The mean size of the HCCs was 23 mm ( 13), with
a range between 7 and 49 mm. The diagnosis was conﬁrmed
by surgical biopsies (n 2), percutaneous biopsy (n 3), or
autopsy (n  4).
Quantitative analysis
The results of the quantitative analysis are summarized in
Table 2.
Hemangiomas
On precontrast T1-weighted SE images, the hemangiomas
appeared hypointense (Fig. 1) and sharply delineated, with a
Fig. 1. Hemangioma and FNH. A On the native T1-weighted
SE sequence (TR, 480 ms; TE, 8 ms), the hemangioma (ar-
row) is strongly hypointense, the FNH (arrowhead) is almost
isointense with respect to the surrounding liver parenchyma.
B After injection of SPIO particles, the hemangioma becomes
highly hyperintense, but the FNH remains isointense. Note
the central hypointense scar in the FNH. C On the native
T2-weighted FSE sequence (TR, 4660 ms; TE, 112 ms; echo
train length, 8), the hemangioma is highly hyperintense, and
the FNH is almost isointense. D After injection of SPIO par-
ticles, both lesions show a signal drop.
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signal-to-noise ratio of 1.13 ( 0.34). On postcontrast
T1-weighted SE images, hemangiomas became hyperin-
tense, with a mean signal ratio of 1.92 ( 0.66). Thus, the
signal ratio showed an increase of 70% on average after
SPIO, which was statistically highly signiﬁcant (p 
0.001).
On T2-weighted FSE images, the hemangiomas were
hyperintense on pre- and postcontrast images. Mean signal
ratios on pre- and postcontrast images were 5.35 ( 3.77)
and 3.56 ( 2.02), respectively. Thus, on postcontrast T2-
weighted images, hemangiomas showed a signiﬁcant signal
drop of 50% (p  0.002).
Focal nodular hyperplasias
On precontrast T1-weighted SE images (Fig. 1), the FNHs
were almost isointense to the liver. The mean signal ratio
was 1.50 ( 0.28). On postcontrast images, the FNHs re-
mained almost isointense to the liver, and the mean signal
ratio was 1.62 ( 0.40). This corresponded to an increase of
8% (p not signiﬁcant).
On T2-weighted FSE images, the FNHs appeared hyper-
intense on pre- and postcontrast images. Mean signal ratios
were 2.96 ( 0.45) and 1.88 ( 0.72) on T2-weighted pre-
and postcontrast images, respectively. This represented a
postcontrast signal drop of 36% (p  0.002).
Metastases
On precontrast T1-weighted SE images, the metastases ap-
peared hypointense or isointense, with a mean signal ratio of
1.71 ( 0.79). On postcontrast T1-weighted SE images, the
mean signal ratio was 1.58 ( 0.74), which was not signif-
icantly different from the signal ratio on the precontrast
image.
On T2-weighted FSE images, the metastases were hyper-
intense on pre- and postcontrast images. The mean signal
ratios were 3.14 ( 1.85) and 3.18 ( 2.40) on pre- and
postcontrast images, respectively, with no signiﬁcant differ-
ence.
Hepatocellular carcinomas
On precontrast T1-weighted SE images, the HCCs appeared
isointense or slightly hyperintense, with a mean signal ratio
of 1.99 ( 0.49). On postcontrast images, they appeared
hyperintense, with a mean signal ratio of 1.92 ( 0.35). This
represented a nonsigniﬁcant signal drop of 3%.
On T2-weighted FSE images, the HCCs appeared hyper-
intense before and after administration of SPIO. The mean
signal ratios were 2.46 ( 0.57) and 3.49 ( 1.47) before
and after contrast agent, respectively. This increase (42%)
was nonsigniﬁcant.
Based on the ROC curves, a 100% speciﬁcity for the
diagnosis of hemangioma on T1-weighted postcontrast im-
Fig. 2. ROC analysis based on pre- and postcontrast SE T1-weighted images. With a cutoff level of 50% signal increase, the
speciﬁcity and sensitivity are 100% and 70%, respectively. The ROC analysis based on the T2-weighted sequence shows a
smaller AUC than that of the T1-weighted sequence.
64 X. Montet et al.: SPIO particles and MRI in liver hemangioma
ages was obtained by using a cutoff value of a 50% signal
intensity ratio increase. The corresponding sensitivity was
70% (Fig. 2).
A 100% speciﬁcity for the diagnosis of hemangioma on
T2-weighted images was obtained by using a cutoff value of
10% of signal intensity ratio. The corresponding sensitivity
was 17%.
The AUC calculated from the T1-weighted sequence
(0.95) was superior to the AUC calculated from the T2-
weighted sequence (0.86). Moreover, for each cutoff value,
the sensibility and speciﬁcity of the postcontrast T1-
weighted sequence were superior to those of the T2-
weighted sequence.
Discussion
Hepatic hemangiomas have a prevalence between 3% and
5% in the general population, according to the literature [5,
9, 22]. Most hemangiomas are small, solitary, asymptomatic
lesions that are discovered incidentally during imaging per-
formed for other clinical indications. Our collective of pa-
tients had 40% multiple hemangiomas, which is above the
reported rate [8]. This result is likely due to the fact that, in
the current study, the patients who underwent MRI had
lesions not adequately characterized by other imaging stud-
ies, especially CT. The presence of multiple lesions is typ-
ically such a situation.
It is generally accepted that patients with a known extra-
hepatic malignancy or patients at high risk for HCC should
undergo imaging in addition to US to conﬁrm or reject the
diagnosis of hemangioma [20]. Commonly, this additional
imaging procedure will entail enhanced CT or MRI, with the
latter including T2-weighted images and a postgadolinium
dynamic T1-weighted sequence. In a certain number of
cases, these two methods do not allow a deﬁnite diagnosis
[23, 24].
Several investigators have considered that the very high
signal intensity of hemangiomas on T2-weighted images is
sufﬁcient for an accurate diagnosis, especially if a long TE in
the range of 180–200 ms, is used. Such long TEs are known
to improve characterization of liver hemangiomas [25–27].
In our study, in which moderately T2-weighted sequences
(TE 112 ms) were used, the intensity of hemangiomas was
on average higher than that of other focal liver lesions, but
with an important overlap of signal intensity between hem-
angiomas and other focal lesions (Fig. 3). From the litera-
ture, it is well known that, on the one hand, liver
hemangiomas can have only moderate hypersignal on T2-
weighted sequences. On the other hand, some metastases can
be hyperintense on T2-weighted images [28]. Thus, intensity
values on T2-weighted images lack speciﬁcity for differen-
tiating hemangiomas from other focal liver lesions, espe-
cially if only a moderately T2-weighted sequence is used
Fig. 3. Signal intensities of individual hemangiomas, metas-
tases and HCCs (diamond shapes) and mean values (bars)
on the T2-weighted FSE sequence (TR, 4660 ms; TE, 112 ms;
echo train length, 8). There is an important overlap between
signal intensities of these lesions. Note the decreased signal
intensity of hemangiomas postinjection of SPIO particles,
thereby increasing the overlap in signal intensity with metas-
tases and HCCs, which explains why the differential diagno-
sis between hemangiomas and malignant tumors is even
more difﬁcult, if only postcontrast images are obtained.
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[29]. Even if morphologic criteria are included, atypical
hemangiomas are still difﬁcult to characterize [28, 30].
Moreover, dynamic CT or MRI can be inconclusive,
especially in cases of very small or very large hemangiomas.
Thus, there is a need for a more speciﬁc method to establish
a clear-cut diagnosis of liver hemangiomas and avoid biop-
sies or even surgical exploration.
We expected that SPIO particles, which do not have the
same type of behavior as iodinated contrast agent on CT,
would provide additional information for the diagnosis of
liver hemangiomas. When we started the current study, our
MR unit did not have the technical requirements to cover the
liver completely with a T1-weighted sequence during the
hepatic arterial phase. We hypothesized that the use of SPIO
particles in association with an SE T1-weighted sequence,
thus obviating a rapid image acquisition, could increase our
conﬁdence for the diagnosis of liver hemangiomas as com-
pared with a T2-weighted sequence alone. Our results con-
ﬁrmed our expectation.
The T2 effect of SPIO particles is well known [10,
31–35]. Because these particles decrease liver signal inten-
sity on T2-weighted sequences and cause no signal change in
lesions that lack Kupffer cells, they increase the lesion-to-
liver contrast and improve lesion detection. Metastases and
Fig. 4. Small hypervascular
hemangioma. A CT shows a
small focal lesion with
homogeneous contrast
enhancement (arrowhead).
This small lesion shows a
signal increase on the post-
SPIO T1-weighted image (C;
arrowhead) as compared
with the precontrast image
(B; arrowhead). This
enhancement pattern is
typical for hemangiomas,
thus enabling the diagnosis,
which was conﬁrmed by
follow-up. D The native FSE
T2-weighted image shows a
relatively hyperintense lesion
that is less intense than the
cephalospinal ﬂuid. E
Postinjection of SPIO, there
is a signal intensity drop of
the lesion.
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HCCs usually do not take up SPIO particles because they
lack Kupffer cells [16, 36, 37], although well-differentiated
HCCs may contain Kupffer cells [38]. SPIO particles also
have a potent r1 relaxivity, with a value of 23.7 mmol/s at
39.5°C and 20 MHz for ferumoxides. Therefore, even if
the r2 relaxivity is higher than the r1 relaxivity (107
mmol/s in the same conditions), we can expect a non-
negligible T1 effect of ferumoxides. This effect is dose
dependent and is observed at low concentrations [39]. In
vivo, such an effect has been reported in hemangiomas on
T1-weighted SE sequences [17] and has been conﬁrmed in
the present study by showing a high speciﬁcity for the
diagnosis of liver hemangiomas. The T1 effect of SPIO
particles is likely time dependent. Immediately after ad-
ministration, large clusters of particles are circulating,
thereby inducing a substantial T2 effect. Within minutes,
Fig. 5. Solitary hemangioma. CT scans of a solitary lesion in
native (A), hepatic arterial phase (B), portal venous phase (C),
and delayed phase (D) show one slightly hypervascular tumor
without rapid washout. Corresponding T1-weighted se-
quences before (E) and after (F) SPIO and T2-weighted im-
ages before (G) and after (H) SPIO. Note the enhancement of
the lesion post-SPIO injection on the T1-weighted sequence.
This lesion was diagnosed as hemangioma and conﬁrmed at
follow-up.
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the larger particles are preferentially sequestered by the
reticulo-endothelial system, whereas the smaller ones,
responsible for the T1 effect, remain in circulation. How-
ever, in our study, we did not evaluate this time depen-
dency because the contrast medium was slowly perfused,
and only late images were acquired (1–1.5 h postinjection
of SPIO particles).
Hemangiomas are the only lesions that have statistically
signiﬁcant enhancement on SE T1-weighted sequences
postinjection of SPIO particles. This increase was on average
70% in our study. A major advantage of using SPIO-en-
hanced MRI for characterizing hemangiomas is that even
atypical hemangiomas on CT can showed enhancement on
T1-weighted SE images (Figs. 4–7). In addition, the ROC
analysis showed that the optimized sensitivity and speciﬁcity
couple is obtained when using a cutoff level of 50% signal
increase. With this cutoff value, the speciﬁcity and sensitiv-
ity are 100% and 70%, respectively. We focused on a test
with excellent speciﬁcity to avoid unnecessary biopsies or
surgical interventions. Moreover, the AUC of the T1-
weighted sequence was higher than that of the native T2-
weighted sequence, indicating a better accuracy of the SPIO-
enhanced T1-weighted sequence, at least for the TE value we
used. The use of a more heavily T2-weighted sequence
might have produced better results, but, as previously men-
tioned, we choose a TE of 112 ms as a compromise to obtain
an acceptable signal-to-noise ratio. In our opinion, positive
enhancement on a T1-weighted sequence postinjection of
Fig. 6. Multiple hypervascular hemangiomas. CT shows
multiple small lesions in native (A), hepatic arterial phase (B),
portal venous phase (C), and delayed phase (D). The three
nodules are hypervascular without rapid washout. Corre-
sponding T1-weighted images before (E) and after (F) SPIO
and T2-weighted images before (G) and after (H) SPIO. Note
the enhancement of the lesions post-SPIO injection on the
T1-weighted sequence. These lesions were diagnosed as
hemangiomas and conﬁrmed at follow-up.
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SPIO particles is complementary to high signal intensity of
hemangiomas on T2-weighted sequences for establishing an
accurate diagnosis.
A major drawback of using SPIO particles is that the
procedure is lengthy, if one performs pre- and postcontrast
imaging. Nevertheless, we strongly believe that precontrast
images are also required for accurate lesion characterization
because they are needed to calculate the signal enhancement
of a lesion. Visual evaluation or even measurement of lesion-
to-liver contrast on post-SPIO particles T1-weighted images
alone is not sufﬁcient. It is necessary to measure the signal
increase between pre- and postcontrast images: an enhance-
ment greater than 50% is characteristic of hemangiomas. On
T2-weighted sequences, signal intensity of hemangiomas is
decreased postinjection of SPIO [40] (Fig. 3), thus making
the differential diagnosis between hemangiomas and malig-
nant lesion more difﬁcult than on precontrast images.
In our institution, we now use SPIO particles routinely
for the deﬁnitive characterization of liver hemangiomas
when CT is inconclusive. Because of potential cardiac
side effects and low back pain, ferumoxides cannot be
injected as a bolus; therefore, a dynamic sequence cannot
be performed. The advent of a new generation of SPIO
particles (Resovist, Schering, Germany), which can be
injected as a bolus, has removed this major limitation.
Dynamic sequences can now be acquired that combines
the advantages of imaging in the vascular phase and the
phase of uptake by the reticuloendothelial system for
improved detection and characterization of focal liver
lesions. Nevertheless, to our knowledge, there has been no
study validating the usefulness of dynamic images using
SPIO particles. The much shorter duration of the MR
examination with Resovist is the most obvious advantage
over Endorem.
Fig. 7. Small hemangioma in a cirrhotic liver. CT scans of a small lesion
in native (A), arterial hepatic phase (B), and portal venous phase (C) show
a hypervascular tumor without rapid washout. Corresponding T1-
weighted sequence before (D) and after (E) SPIO and T2-weighted
images before (F) and after (G) SPIO. Note the enhancement of the lesion
post-SPIO injection on the T1-weighted sequence. This lesion was
diagnosed as hemangioma and conﬁrmed by histology after liver
transplantation.
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In conclusion, when SPIO particles are used as a contrast
agent for liver imaging, the addition of a T1-weighted se-
quence is useful because it helps to characterize hemangio-
mas and to differentiate them from other solid liver lesions.
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